The Lancet. Infectious diseases
Biomarkers for tuberculosis disease activity, cure, and relapse.
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
STREAM: a pragmatic and explanatory trial for MDR-TB treatment.
Drug-resistant tuberculosis: time for visionary political leadership.
Improving the cascade of global tuberculosis care: moving from the "what" to the "how" of quality improvement.
Antimalarial drug resistance in Africa: the calm before the storm?
Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings.
Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis.
